Alpha-1 Antitrypsin Deficiency: Principles of Care
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10316/105540 https://doi.org/10.20344/amp.12950 |
Resumo: | Alpha-1 antitrypsin deficiency is an autosomal co-dominant inherited disorder that results in decreased circulating levels of alpha-1 antitrypsin (also known as alpha-1 proteinase inhibitor) and predisposes affected individuals to early onset lung and liver disease. There is currently no cure for alpha-1 antitrypsin deficiency. However, appropriate treatment and a high standard of clinical care can prevent patients from being seriously affected and having to undergo major medical interventions, such as organ transplantation. Beyond managing the symptoms associated with alpha-1 antitrypsin deficiency, alpha-1 proteinase inhibitor therapy is the only treatment for the condition's underlying cause. Early diagnosis is important to ensure efficient therapeutic strategies and to minimize further deterioration of lung function. alpha-1 antitrypsin deficiency is under diagnosed globally, partly because the disease has no unique presenting symptoms. This document was prepared by a Portuguese multidisciplinary group and it aims to set out comprehensive principles of care for Alpha-1 antitrypsin deficiency. These include the importance of registries, the need for clinical research, the need for consistent recommendations (regarding diagnosis, treatment and monitoring), the role of reference centres, the requirement for sustained access to treatment, diagnostic and support services, and the role of patient organizations. |
id |
RCAP_77aa9b253b89f50d3af34d8e8f2aa35f |
---|---|
oai_identifier_str |
oai:estudogeral.uc.pt:10316/105540 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Alpha-1 Antitrypsin Deficiency: Principles of Carealpha 1-Antitrypsin Deficiency/therapyHealth Care Quality, Access, and EvaluationProfessional PracticeStandard of CareAcesso e Avaliação dos Cuidados de SaúdeDeficiência de alfa 1–Antitripsina/tratamento;Padrão de CuidadoQualidade, Prática ProfisionalHumansPractice Guidelines as Topicalpha 1-Antitrypsin DeficiencyStandard of CareAlpha-1 antitrypsin deficiency is an autosomal co-dominant inherited disorder that results in decreased circulating levels of alpha-1 antitrypsin (also known as alpha-1 proteinase inhibitor) and predisposes affected individuals to early onset lung and liver disease. There is currently no cure for alpha-1 antitrypsin deficiency. However, appropriate treatment and a high standard of clinical care can prevent patients from being seriously affected and having to undergo major medical interventions, such as organ transplantation. Beyond managing the symptoms associated with alpha-1 antitrypsin deficiency, alpha-1 proteinase inhibitor therapy is the only treatment for the condition's underlying cause. Early diagnosis is important to ensure efficient therapeutic strategies and to minimize further deterioration of lung function. alpha-1 antitrypsin deficiency is under diagnosed globally, partly because the disease has no unique presenting symptoms. This document was prepared by a Portuguese multidisciplinary group and it aims to set out comprehensive principles of care for Alpha-1 antitrypsin deficiency. These include the importance of registries, the need for clinical research, the need for consistent recommendations (regarding diagnosis, treatment and monitoring), the role of reference centres, the requirement for sustained access to treatment, diagnostic and support services, and the role of patient organizations.A deficiência de alfa-1 antitripsina é uma doença hereditária autossómica co-dominante que resulta numa diminuição dos níveis plasmáticos de alfa-1 antitripsina (também conhecida por inibidor da alfa-1 proteinase) e predispõe os indivíduos afetados ao desenvolvimento de doença pulmonar e hepática precoce. Atualmente não existe cura para a deficiência de alfa-1 antitripsina. No entanto, o tratamento adequado e um elevado padrão de cuidados clínicos podem prevenir que os doentes sejam gravemente afetados e terem que se submeter a intervenções médicas major, como o transplante de órgão. Para além de atuar nos sintomas associados à deficiência de alfa-1 antitripsina, a terapêutica com o inibidor da alfa-1 proteinase é o único tratamento disponível que atua na causa subjacente desta patologia. O diagnostico precoce é importante para assegurar a implementação de estratégias terapêuticas eficientes e para minimizar a destruição adicional da função pulmonar. A deficiência de alfa-1 antitripsina está globalmente sub diagnosticada, em parte devido ao fato desta doença não apresentar sintomas únicos. Este documento foi preparado por um grupo multidisciplinar e visa estabelecer princípios de cuidados abrangentes para a deficiência de alfa-1 antitripsina. Estes incluem a importância dos registros, a necessidade de investigação clinica, a necessidade de recomendações consistentes (no que diz respeito ao diagnostico, tratamento e monitorização), o papel dos centros de referência, a necessidade de acesso sustentado ao tratamento, diagnostico e serviços de suporte, e o papel das associações de doentes.Ordem dos Médicos2020-06-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://hdl.handle.net/10316/105540http://hdl.handle.net/10316/105540https://doi.org/10.20344/amp.12950eng1646-07580870-399XRodrigues, Joana FMineiro, AlexandraReis, AntónioVentura, David G.Fernandez-Llimos, FernandoCosta, FilipaGomes, JoanaSilva, José ManuelLopes, PauloCordeiro, Carlos R.info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-03-06T12:25:13Zoai:estudogeral.uc.pt:10316/105540Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:22:06.084542Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Alpha-1 Antitrypsin Deficiency: Principles of Care |
title |
Alpha-1 Antitrypsin Deficiency: Principles of Care |
spellingShingle |
Alpha-1 Antitrypsin Deficiency: Principles of Care Rodrigues, Joana F alpha 1-Antitrypsin Deficiency/therapy Health Care Quality, Access, and Evaluation Professional Practice Standard of Care Acesso e Avaliação dos Cuidados de Saúde Deficiência de alfa 1–Antitripsina/tratamento; Padrão de Cuidado Qualidade, Prática Profisional Humans Practice Guidelines as Topic alpha 1-Antitrypsin Deficiency Standard of Care |
title_short |
Alpha-1 Antitrypsin Deficiency: Principles of Care |
title_full |
Alpha-1 Antitrypsin Deficiency: Principles of Care |
title_fullStr |
Alpha-1 Antitrypsin Deficiency: Principles of Care |
title_full_unstemmed |
Alpha-1 Antitrypsin Deficiency: Principles of Care |
title_sort |
Alpha-1 Antitrypsin Deficiency: Principles of Care |
author |
Rodrigues, Joana F |
author_facet |
Rodrigues, Joana F Mineiro, Alexandra Reis, António Ventura, David G. Fernandez-Llimos, Fernando Costa, Filipa Gomes, Joana Silva, José Manuel Lopes, Paulo Cordeiro, Carlos R. |
author_role |
author |
author2 |
Mineiro, Alexandra Reis, António Ventura, David G. Fernandez-Llimos, Fernando Costa, Filipa Gomes, Joana Silva, José Manuel Lopes, Paulo Cordeiro, Carlos R. |
author2_role |
author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Rodrigues, Joana F Mineiro, Alexandra Reis, António Ventura, David G. Fernandez-Llimos, Fernando Costa, Filipa Gomes, Joana Silva, José Manuel Lopes, Paulo Cordeiro, Carlos R. |
dc.subject.por.fl_str_mv |
alpha 1-Antitrypsin Deficiency/therapy Health Care Quality, Access, and Evaluation Professional Practice Standard of Care Acesso e Avaliação dos Cuidados de Saúde Deficiência de alfa 1–Antitripsina/tratamento; Padrão de Cuidado Qualidade, Prática Profisional Humans Practice Guidelines as Topic alpha 1-Antitrypsin Deficiency Standard of Care |
topic |
alpha 1-Antitrypsin Deficiency/therapy Health Care Quality, Access, and Evaluation Professional Practice Standard of Care Acesso e Avaliação dos Cuidados de Saúde Deficiência de alfa 1–Antitripsina/tratamento; Padrão de Cuidado Qualidade, Prática Profisional Humans Practice Guidelines as Topic alpha 1-Antitrypsin Deficiency Standard of Care |
description |
Alpha-1 antitrypsin deficiency is an autosomal co-dominant inherited disorder that results in decreased circulating levels of alpha-1 antitrypsin (also known as alpha-1 proteinase inhibitor) and predisposes affected individuals to early onset lung and liver disease. There is currently no cure for alpha-1 antitrypsin deficiency. However, appropriate treatment and a high standard of clinical care can prevent patients from being seriously affected and having to undergo major medical interventions, such as organ transplantation. Beyond managing the symptoms associated with alpha-1 antitrypsin deficiency, alpha-1 proteinase inhibitor therapy is the only treatment for the condition's underlying cause. Early diagnosis is important to ensure efficient therapeutic strategies and to minimize further deterioration of lung function. alpha-1 antitrypsin deficiency is under diagnosed globally, partly because the disease has no unique presenting symptoms. This document was prepared by a Portuguese multidisciplinary group and it aims to set out comprehensive principles of care for Alpha-1 antitrypsin deficiency. These include the importance of registries, the need for clinical research, the need for consistent recommendations (regarding diagnosis, treatment and monitoring), the role of reference centres, the requirement for sustained access to treatment, diagnostic and support services, and the role of patient organizations. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-06-01 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10316/105540 http://hdl.handle.net/10316/105540 https://doi.org/10.20344/amp.12950 |
url |
http://hdl.handle.net/10316/105540 https://doi.org/10.20344/amp.12950 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
1646-0758 0870-399X |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Ordem dos Médicos |
publisher.none.fl_str_mv |
Ordem dos Médicos |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1817552189296476160 |